XTalks

OCTOBER 12, 2022

We [Philips Pharma Solutions, formerly BioTel Research] have successfully ran multi-site DCE-MRI trials,” said Edward Ashton, PhD, VP, Oncology Imaging, Philips Pharma Solutions. An Example of an Anti-Angiogenic Therapy in Oncology. An Example of an Anti-Vascular Therapy in Oncology. Introduction to Perfusion Imaging.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

Delveinsight

FEBRUARY 25, 2021

Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing. Combining immuno-oncology treatments such as checkpoint inhibitors with other cancer-killing drugs is considered a remarkable strategy for enhancing the response rate to immunotherapy.

DNA 52

DNA In-Vivo Genetics Medicine 52

XTalks

DECEMBER 21, 2022

The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. The majority of gene therapies approved and under development are in the areas of oncology and rare disease.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

XTalks

JANUARY 19, 2024

Dose Delivery There have also been significant improvements in the precision of dose delivery. In external beam radiotherapy, precisely aimed beams of radiation have been developed to deliver highly localized and targeted radiation, such as stereotactic radiosurgery in which the aim is to sterilize the tissue within the targeted region.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 9, 2023

Following this, Rebecca Croasdale-Wood, PhD, Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca, will present: ‘Benchmarking the impact of AI biologics discovery and optimisation for pharma’. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

XTalks

MARCH 22, 2023

2014 saw multiple business unit buyouts in the industry, with Novartis acquiring GlaxoSmithKline’s oncology arm and Bayer taking over Merck’s consumer health business. At the same time, the industry has seen a massive shift from a “one-pill-fits-all” style of drug development to a precision medicine focus.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97